

FOI REF: 26/741

23rd October 2026

Eastbourne District General Hospital

Kings Drive
Eastbourne
East Sussex
BN21 2UD

Tel: 0300 131 4500
Website: www.esht.nhs.uk

Further to your recent request for information made under the Freedom of Information Act (FOIA) 2000, I now set out our answers to your specific questions, and any clarifications sought and provided, as follows:

I would highly value your support in answering the questions below regarding the number of patients treated with the medicines listed between the first of July 2026 to the 30th of September 2026, or the latest three-month period for which data is available. Please include information for all hospitals in the Trust.

1. How many patients were treated in total, regardless of diagnosis, with these medicines in the 3 months between July 2026 to the end of September 2026, or latest 3-months for which data are available?

Name of medicine	Number patients treated
1.1 Abiraterone (Zytiga or generic abiraterone)	28
1.2 Apalutamide (Erleada)	6
1.3 Cabazitaxel	2
1.4 Darolutamide (Nubeqa)	79
1.5 Docetaxel	48
1.6 Enzalutamide (Xtandi)	202
1.7 Lutetium-177 PSMA-617 (Pluvicto)	0
1.8 Olaparib (Lynparza)	15
1.9 Relugolix (Orgovyx, Ryeqo)	0
1.10 Talazoparib (Talzenna)	0

2. How many patients were treated with these products specifically for prostate cancer (ICD-10 code = C61) in the 3 months between July 2026 to the end of September 2026, or latest 3-months for which data are available?

Name of medicine	Number patients treated
2.1 Docetaxel for prostate cancer	6
2.2 Olaparib (Lynparza) for prostate cancer	0
2.3 Talazoparib (Talzenna) for prostate cancer	0
2.4 Relugolix (Orgovyx) for prostate cancer	0

3. How many patients received their first cycle or first dose of the following products in the 3 months between 1st April 2026 to the end of June 2026, or latest 3-months for which data are available?

Name of medicine	Number patients treated in Cycle 1 or Dose 1
3.1 Abiraterone (Zytiga or generic abiraterone)	2
3.2 Apalutamide (Erleada)	0
3.3 Cabazitaxel (Jevtana or generic cabazitaxel)	0
3.4 Darolutamide (Nubeqa)	28
3.5 Enzalutamide (Xtandi)	11

4. How many patients were treated with the following combinations in the 3 months between July 2026 to the end of September 2026, or latest 3-months for which data are available? Please give total number of patients and number of patients receiving their first dose or first cycle.

Name of medicine	<u>Total</u> Number patients treated	Number patients received <u>cycle 1</u> or <u>dose 1</u>
4.1 Darolutamide (Nubeqa) + Docetaxel	2	1
4.2 Darolutamide (Nubeqa) monotherapy	65	31
4.3 Olaparib (Lynparza) + Abiraterone	0	0

5. How many patients were switched from the following products to darolutamide (Nubeqa) in the 3 months between July 2026 to the end of September 2026, or latest 3-months for which data are available?

Name of medicine	Number patients switched
5.1 Abiraterone	0
5.2 Apalutamide	0
5.3 Enzalutamide	8

6. How many patients received the following products for non-metastatic hormone sensitive prostate cancer in the 3 months between July 2026 to the end of September 2026, or latest 3-months for which data are available?

Name of medicine	Number patients treated
6.1 Abiraterone	10
6.2 Enzalutamide	4

7. How many patients were treated with darolutamide (Nubeqa) for the following indications and BlueTeq CDF codes between July 2026 to the end of September 2026?

BlueTeq CDF code	BlueTeq CDF description (copied from CDF List)	Number of patients
DARO1	Darolutamide for non-metastatic hormone-resistant (castration-resistant) prostate cancer	9
DARO2	Darolutamide in combination with docetaxel and ADT for patients with newly diagnosed metastatic hormone-sensitive prostate cancer	21
DARO3	Darolutamide in combination with ADT for patients with newly diagnosed metastatic hormone-sensitive prostate cancer who are unsuitable for treatment with docetaxel	49

8. How many patients received Cemiplimab (Libtayo) for Non-small Cell Lung Cancer in the 3 months between July 2026 to the end of September 2026, or latest 3-months for which data are available?

Product	Number patients treated
8.1 Cemiplimab (Libtayo) for <u>Non-small Cell Lung Cancer</u>	0

9. How many patients received Cemiplimab (Libtayo) for Non-small Cell Lung Cancer in combination or as monotherapy in the 3 months between July 2026 to the end of September 2026, or latest 3-months for which data are available?

Combination or monotherapy for <u>Non-small Cell Lung Cancer</u>	Number patients treated
9.1 Cemiplimab + Cisplatin or Carboplatin chemotherapy	0
9.2 Cemiplimab monotherapy	0

10. How many patients received the following products in the 3 months between July 2026 to the end of September 2026, or latest 3-months for which data are available?

Product	Number patients treated
10.1 Amivantamab (Rybrevant)	1
10.2 Lazertinib (Lazcluze)	1
10.3 Osimertinib (Tagrisso)	24

11. How many patients received the following products in combination or as monotherapy in the 3 months between July 2026 to the end of September 2026?

Product	Number patients treated
11.1 Amivantamab + Lazertinib	1
11.2 Amivantamab + Carboplatin + Pemetrexed	0
11.3 Amivantamab Monotherapy	0
11.4 Osimertinib + Pemetrexed + Platinum Chemotherapy	0
11.5 Osimertinib Monotherapy	22

12. How many patients received Osimertinib (Tagrisso) as Adjuvant treatment in the 3 months between July 2026 to the end of September 2026, or latest 3-months for which data are available?

Product	Number patients treated
12.1 Osimertinib as adjuvant treatment	17

I trust this information is helpful in its detail or explanation however, if you are dissatisfied with the response, then you have the right to request an internal review. If you wish to seek an internal review, please write to the Freedom of Information Team at esh-tr.foi@nhs.net quoting the above FOI reference number, within 40 working days. Please note the Trust is not obliged to accept a request for an internal review after this time period.

Yours faithfully

Freedom of Information (FOI) Team
East Sussex Healthcare NHS Trust
0300 131 4716
Core Hours of Business: Monday to Friday 9.00am to 4.00pm